BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 35109866)

  • 1. Tumor angiogenesis at baseline identified by
    Wei Y; Qin X; Liu X; Zheng J; Luan X; Zhou Y; Yu J; Yuan S
    J Transl Med; 2022 Feb; 20(1):63. PubMed ID: 35109866
    [TBL] [Abstract][Full Text] [Related]  

  • 2.
    Luan X; Huang Y; Gao S; Sun X; Wang S; Ma L; Teng X; Lu H; Yu J; Yuan S
    Eur J Nucl Med Mol Imaging; 2016 Dec; 43(13):2336-2342. PubMed ID: 27631310
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship Between Clinicopathological Characteristics and PET/CT Uptake in Esophageal Squamous Cell Carcinoma: [
    Dong Y; Wei Y; Chen G; Huang Y; Song P; Liu S; Zheng J; Cheng M; Yuan S
    Mol Imaging Biol; 2019 Feb; 21(1):175-182. PubMed ID: 29869060
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The predictive value of
    Mattoli MV; Massaccesi M; Castelluccia A; Scolozzi V; Mantini G; Calcagni ML
    Radiat Oncol; 2017 Jan; 12(1):4. PubMed ID: 28057034
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early Change in Metabolic Tumor Heterogeneity during Chemoradiotherapy and Its Prognostic Value for Patients with Locally Advanced Non-Small Cell Lung Cancer.
    Dong X; Sun X; Sun L; Maxim PG; Xing L; Huang Y; Li W; Wan H; Zhao X; Xing L; Yu J
    PLoS One; 2016; 11(6):e0157836. PubMed ID: 27322376
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic Significance of Standardized Uptake Value of Lymph Nodes on Survival for Stage III Non-small Cell Lung Cancer Treated With Definitive Concurrent Chemoradiotherapy.
    Lee VH; Chan WW; Lee EY; Choy TS; Ho PP; Leung DK; Lam KO; Kwong DL; Leung TW; Khong PL
    Am J Clin Oncol; 2016 Aug; 39(4):355-62. PubMed ID: 24710123
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Pilot Study of
    Zhou Y; Gao S; Huang Y; Zheng J; Dong Y; Zhang B; Zhao S; Lu H; Liu Z; Yu J; Yuan S
    Sci Rep; 2017 Jun; 7(1):2877. PubMed ID: 28588317
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic importance of
    Kanyilmaz G; Benli Yavuz B; Aktan M; Sahin O
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2020; 39(1):20-26. PubMed ID: 31668790
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Response Prediction Using
    Hu X; Zhou T; Ren J; Duan J; Wu H; Liu X; Mu Z; Liu N; Wei Y; Yuan S
    J Nucl Med; 2023 Apr; 64(4):625-631. PubMed ID: 36229183
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Volume-Based Assessment With 18F-FDG PET/CT Improves Outcome Prediction for Patients With Stage IIIA-N2 Non-Small Cell Lung Cancer.
    Hyun SH; Ahn HK; Ahn MJ; Ahn YC; Kim J; Shim YM; Choi JY
    AJR Am J Roentgenol; 2015 Sep; 205(3):623-8. PubMed ID: 26295651
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparing the Diagnostic Potential of 68Ga-Alfatide II and 18F-FDG in Differentiating Between Non-Small Cell Lung Cancer and Tuberculosis.
    Kang F; Wang S; Tian F; Zhao M; Zhang M; Wang Z; Li G; Liu C; Yang W; Li X; Wang J
    J Nucl Med; 2016 May; 57(5):672-7. PubMed ID: 26719378
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early metabolic response on 18F-fluorodeoxyglucose-positron-emission tomography/computed tomography after concurrent chemoradiotherapy for advanced stage III non-small cell lung cancer is correlated with local tumor control and survival.
    Jeong JU; Chung WK; Nam TK; Song JY; Yoon MS; Kim YC; Kim KS; Oh IJ; Ban HJ; Kwon SY; Bom HS; Ahn SJ
    Anticancer Res; 2014 May; 34(5):2517-23. PubMed ID: 24778069
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination of Fluorine-18 Fluorodeoxyglucose Positron-Emission Tomography/Computed Tomography (¹⁸F-FDG PET/CT) and Tumor Markers to Diagnose Lymph Node Metastasis in Non-Small Cell Lung Cancer (NSCLC): A Retrospective and Prospective Study.
    Zhai X; Guo Y; Qian X
    Med Sci Monit; 2020 Jun; 26():e922675. PubMed ID: 32483109
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A pilot study imaging integrin αvβ3 with RGD PET/CT in suspected lung cancer patients.
    Gao S; Wu H; Li W; Zhao S; Teng X; Lu H; Hu X; Wang S; Yu J; Yuan S
    Eur J Nucl Med Mol Imaging; 2015 Dec; 42(13):2029-37. PubMed ID: 26153145
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The early predictive value of a decrease of metabolic tumor volume in repeated (18)F-FDG PET/CT for recurrence of locally advanced non-small cell lung cancer with concurrent radiochemotherapy.
    Huang W; Liu B; Fan M; Zhou T; Fu Z; Zhang Z; Li H; Li B
    Eur J Radiol; 2015 Mar; 84(3):482-488. PubMed ID: 25533718
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of PET/CT standardized uptake values on complete response to treatment before definitive chemoradiotherapy in stage III non-small cell lung cancer.
    Ercelep O; Alan O; Sahin D; Telli TA; Salva H; Tuylu TB; Babacan NA; Kaya S; Dane F; Ones T; Alkis H; Adli M; Yumuk F
    Clin Transl Oncol; 2019 Apr; 21(4):499-504. PubMed ID: 30229391
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Are pretreatment 18F-FDG PET tumor textural features in non-small cell lung cancer associated with response and survival after chemoradiotherapy?
    Cook GJ; Yip C; Siddique M; Goh V; Chicklore S; Roy A; Marsden P; Ahmad S; Landau D
    J Nucl Med; 2013 Jan; 54(1):19-26. PubMed ID: 23204495
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Can an ¹⁸F-ALF-NOTA-PRGD2 PET/CT Scan Predict Treatment Sensitivity to Concurrent Chemoradiotherapy in Patients with Newly Diagnosed Glioblastoma?
    Zhang H; Liu N; Gao S; Hu X; Zhao W; Tao R; Chen Z; Zheng J; Sun X; Xu L; Li W; Yu J; Yuan S
    J Nucl Med; 2016 Apr; 57(4):524-9. PubMed ID: 26514171
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Standard uptake value and metabolic tumor volume of ¹⁸F-FDG PET/CT predict short-term outcome early in the course of chemoradiotherapy in advanced non-small cell lung cancer.
    Huang W; Zhou T; Ma L; Sun H; Gong H; Wang J; Yu J; Li B
    Eur J Nucl Med Mol Imaging; 2011 Sep; 38(9):1628-35. PubMed ID: 21617977
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor to liver maximum standardized uptake value ratio of FDG-PET/CT parameters predicts tumor treatment response and survival of stage III non-small cell lung cancer.
    Zhang P; Chen W; Zhao K; Qiu X; Li T; Zhu X; Sun P; Wang C; Song Y
    BMC Med Imaging; 2023 Aug; 23(1):107. PubMed ID: 37582701
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.